Chemomab Therapeutics Ltd. (CMMB) intrinsic value & 10-year financials
Chemomab Therapeutics Ltd. (CMMB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.26
- Market cap
- $287.9M
- Revenue (FY2022)
- —
- ROIC (10-yr avg)
- 316.5%
- Free cash flow (FY2022)
- -$20.4M
CMMB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2022 | — | -$27.6M | $0.12 | -$20.4M | — | -79.8% |
| FY2021 | — | -$12.5M | $0.06 | -$12.6M | — | -55.8% |
| FY2020 | — | -$11.6M | — | -$12.7M | — | 620.8% |
| FY2019 | — | -$27.1M | — | -$16.6M | — | 1397.4% |
| FY2018 | — | -$13.8M | — | -$14.4M | — | -300.1% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Chemomab Therapeutics Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Chemomab Therapeutics Ltd. has historically struggled to out-earn its cost of capital, averaging just -23.7% ROIC.
Chemomab Therapeutics Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Chemomab Therapeutics Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.